AIFM3: A Potent Drug Target and Potential Biomarker for Apoptosis-Inducing Factor 3

Target Name: AIFM3

NCBI ID: G150209

AIFM3

AIFM3: A Potent Drug Target and Potential Biomarker for Apoptosis-Inducing Factor 3

Introduction

Apoptosis, the natural cell death process, plays a crucial role in various biological processes, including development, tissue repair, and immune response. However, when aberrant or excessive cell death occurs, it can lead to diseases such as cancer, neurodegenerative disorders, and diseases associated with misfolded proteins. The protein AIFM3, also known as Apoptosis-inducing Factor 3, has been identified as a potential drug target and biomarker for various diseases.

In this article, we will discuss AIFM3, its functions, and potential as a drug target and biomarker.

FUNCTION OF AIFM3

AIFM3 is a 21-kDa protein that is expressed in various tissues and cells, including brain, heart, liver, and cancer cells. It is a key regulator of apoptosis, which is the natural cell death process that occurs in response to various stressors, such as UV radiation, chemotherapy, and telomere shortening. Under normal circumstances, AIFM3 controls apoptosis by inhibiting apoptosis signaling pathways, such as the apoptosis inducer (BAX)/apoptosis receptor (BRD4) pathway. However, when AIFM3 gene expression is dysregulated or its function is altered, the apoptosis process may be disrupted, leading to disease.

The relationship between abnormal expression of AIFM3 and various diseases has been extensively studied. For example, overexpression of AIFM3 is closely associated with the development of neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, as well as certain cancers, such as liver cancer and breast cancer. In addition, the interaction of AIFM3 with the apoptosis inducer (BAX) and apoptosis receptor (BRD4) pathways has also been confirmed to be closely related to the progression and treatment response of various cancers.

As a drug target, inhibition of AIFM3 can significantly inhibit cell apoptosis, thereby providing new ideas for the treatment of various diseases. Currently, a variety of drugs that inhibit AIFM3 expression have entered clinical research, such as the anti-tumor drug doxorubicin and the anti-apoptotic drug bevacizumab.

As a biomarker, the expression level of AIFM3 can be used as a biomarker to monitor disease progression and treatment efficacy. By detecting the expression level of AIFM3, the survival time and treatment response of disease patients can be predicted. In addition, the reduction in AIFM3 expression levels can also be used as an indicator of the effectiveness of disease treatment.

POTENTIAL AS A DRUG TARGET

AIFM3 has been identified as a potential drug target due to its central role in the regulation of apoptosis. Its inhibition has been shown to be effective in various diseases, including neurodegenerative disorders, cancer, and neuroinflammation.

One of the key reasons for AIFM3's potential as a drug target is its involvement in the BAX/BRD4 pathway, which is a well-established target for anti-apoptotic drugs. Inhibition of the BAX/BRD4 pathway can significantly inhibit apoptosis, thereby providing therapeutic A variety of diseases provide new ideas.

Another reason for AIFM3's potential as a drug target is its expression in various tissues and cells, including brain, heart, liver, and cancer cells. This makes it a potential target for small molecules that can cross-talk with AIFM3 in these tissues.

As a drug target, AIFM3 can be targeted with small molecules, including inhibitors of theBAX/BRD4 pathway, as well as inhibitors of AIFM3's activity. Studies have shown that AIFM3 inhibitors can be effective in preclinical models of neurodegenerative disorders, cancer, and neuroinflammation.

Moreover, AIFM3 has been shown to be involved in

Protein Name: Apoptosis Inducing Factor Mitochondria Associated 3

Functions: Induces apoptosis through a caspase dependent pathway. Reduces mitochondrial membrane potential

The "AIFM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AIFM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets